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Introduction
The most common form of
lymphoma, diffuse large B-cell
lymphoma (DLBCL), is often
characterized by gene duplication of
TCF4, an E2 basic helix-loop-helix
transcription factor. The TCF4 gene
is closely related to TCF3, which is
negatively regulated by ID2 and ID3.
The ID proteins negatively regulate
cellular differentiation and induce
proliferation by inhibiting the activity
of TCF3 and TCF4 through
heterodimer formation. Due to their
implication in tumorigenesis, these
genes may be potential therapeutic
targets for DLBCL tumors resistant
to current immuno-chemotherapies.
The CRISPR-Cas9 system is an
effective tool for editing the genome
of human cancer cell lines. For cell
lines that are difficult to transfect,
electroporation facilitates the entry
of a designed guide RNA and Cas9
nuclease. DNA repair can then
occur by one of two pathways: nonhomologous end joining or
homology-directed repair. The
resulting knockout of a gene or
introduction of a specific mutation
allows for study of cancer prognosis
and treatments.

Results

Conclusions
CRISPR-Cas9 editing of the ID3
gene resulted in indel mutations in
two clones, A4 and B12. These
mutations alter the reading frame,
causing a frame shift.

Fig. 2 The CRISPR-Cas9 system successfully edited the ID3 gene. The DG-75 clone B15
was transfected with PX458-ID3-g1 using an electroporation protocol. Sequencing of cell
clones identified whether indel mutations occurred in the ID3 gene. Clone A4 had one guanine
inserted, clones A20 and B3 were not edited, and clone B12 had one guanine deleted.

Fig. 3 Indel mutations in the ID3
gene resulted in an absence of
protein expression. A western blot
was performed to determine the
presence of the ID3 protein. Clones
A20 and B3 were unedited and
expressed ID3, as indicated by the
presence of a band. The edited
clones, A4 and B12, do not show
expression, similar to the negative
control HBL-1, an established
DLBCL cell line.

Western blotting determined whether
mutations affected the expression of
the ID3 protein in each respective
clone compared to wild type.

Acknowledgments
I would like to thank Qing Deng and
all other members of the Green lab
for their mentorship. Thank you to
the University of Notre Dame for
funding my summer experience.

References
Hasskarl, J., & Münger, K. (2002). Id
proteins--tumor markers or oncogenes?.
Cancer biology & therapy, 1(2), 91–96.

Methodology
Electroporation and the CRISPRCas9 system were used to introduce
insertion-deletion (indel) mutations in
the ID3 gene. Sequencing was
performed to characterize any
resulting mutations.

To test whether this effectively
knocked out the gene, a western
blot was performed. The A4 and
B12 lines produced no ID3 protein
band, meaning little to no
expression occurred. Thus, these
edited lines may be effective tools
for studying tumorigenesis and the
interaction between ID3 and TCF3.
In addition, future studies could be
done using the cancer drugs
OTX015 and Venetoclax.

Fig. 1a Cas9 nuclease and
guide RNA form a complex
capable of creating a double
stranded break in DNA.

Fig. 1b Repair of the cleaved
DNA leads to the insertion or
deletion of base pairs. Indel
mutations may lead to a
truncated or non-functional
protein.
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